BR9912988A - Composição farmacêutica e método de desenvolvimento de atividade neuronial em animal - Google Patents

Composição farmacêutica e método de desenvolvimento de atividade neuronial em animal

Info

Publication number
BR9912988A
BR9912988A BR9912988-4A BR9912988A BR9912988A BR 9912988 A BR9912988 A BR 9912988A BR 9912988 A BR9912988 A BR 9912988A BR 9912988 A BR9912988 A BR 9912988A
Authority
BR
Brazil
Prior art keywords
animal
pharmaceutical composition
neuronal activity
development
activity
Prior art date
Application number
BR9912988-4A
Other languages
English (en)
Inventor
Jia-He Li
Joseph P Steiner
Gregory S Hamiltom
Original Assignee
Guilford Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Guilford Pharm Inc filed Critical Guilford Pharm Inc
Publication of BR9912988A publication Critical patent/BR9912988A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

<B>COMPOSIçãO FARMACêUTICA E MéTODO DE DESENVOLVIMENTO DE ATIVIDADE NEURONIAL EM ANIMAL<D> Esta invenção refere-se a composições farmacêuticas e métodos para desenvolver atividade neuronial usando carbamatos e uréias de moléculas pequenas, de baixo peso molecular, com afinidade para imunofilinas do tipo FKBP.
BR9912988-4A 1998-08-25 1999-08-24 Composição farmacêutica e método de desenvolvimento de atividade neuronial em animal BR9912988A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/139,672 US6242468B1 (en) 1997-02-27 1998-08-25 Carbamate and urea compositions and neurotrophic uses
PCT/US1999/019261 WO2000010553A2 (en) 1998-08-25 1999-08-24 Carbamate and urea compositions and neurotrophic uses

Publications (1)

Publication Number Publication Date
BR9912988A true BR9912988A (pt) 2001-10-02

Family

ID=22487769

Family Applications (1)

Application Number Title Priority Date Filing Date
BR9912988-4A BR9912988A (pt) 1998-08-25 1999-08-24 Composição farmacêutica e método de desenvolvimento de atividade neuronial em animal

Country Status (18)

Country Link
US (1) US6242468B1 (pt)
EP (1) EP1107757A2 (pt)
JP (1) JP2002523367A (pt)
KR (1) KR20010072992A (pt)
CN (1) CN1313767A (pt)
AU (1) AU5687999A (pt)
BG (1) BG105340A (pt)
BR (1) BR9912988A (pt)
CA (1) CA2341530A1 (pt)
CZ (1) CZ2001274A3 (pt)
EA (1) EA200100271A1 (pt)
HU (1) HUP0103166A3 (pt)
IL (1) IL140958A0 (pt)
MX (1) MXPA01001937A (pt)
NO (1) NO20010946L (pt)
PL (1) PL346759A1 (pt)
SK (1) SK2562001A3 (pt)
WO (1) WO2000010553A2 (pt)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7008960B1 (en) 1999-03-02 2006-03-07 Vitreo-Retinal Technologies, Inc. Agents for intravitreal administration to treat or prevent disorders of the eye
EP1196386A2 (en) * 1999-07-06 2002-04-17 Vertex Pharmaceuticals Incorporated N-substituted glycine derivatives
US20030199574A1 (en) * 2000-03-02 2003-10-23 Vitreo-Retinal Technologies, Inc. Treatment of ophthalmic disorders using urea and urea derivatives
US7977385B2 (en) * 2000-03-02 2011-07-12 Numoda Biotechnologies, Inc. Agents for corneal or intrastromal administration to treat or prevent disorders of the eye
US20050137124A1 (en) * 2002-08-09 2005-06-23 Vitreo-Retinal Technologies, Inc. A California Corporation Agents for intravitreal administration to treat or prevent disorders of the eye
EP1402888A1 (en) * 2002-09-18 2004-03-31 Jerini AG The use of substituted carbocyclic compounds as rotamases inhibitors
US20050197356A1 (en) * 2004-03-02 2005-09-08 Wyeth Non-immunosuppressive immunophilin ligands as neuroprotective and/or neuroregenerative agents
EP1720886A1 (en) 2004-03-02 2006-11-15 Wyeth Macrolides and methods for producing same
WO2007061554A2 (en) * 2005-10-21 2007-05-31 Purdue Research Foundation Dosage of 4-aminopyridine derivatives for treatment of central nervous system injuries
CN104136413B (zh) * 2011-12-27 2016-10-26 比皮艾思药物研发有限公司 用于预防或治疗癫痫症的苯基氨基甲酸酯化合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI874163A (fi) 1986-09-26 1988-03-27 Mitsui Toatsu Chemicals Katekolderivat samt preparat innehaollande desamma foer haemmande och botande av regressiva sjukdomar i det centrala nervsystemet.
US5214034A (en) 1986-09-26 1993-05-25 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives, and preventive and remedial preparations for regressive disorders in the central nervous system containing the same
IT1206078B (it) 1987-06-03 1989-04-14 Polifarma Spa Procedimento per la produzione di acido 3-indolpiruvico e suoi derivati loro uso farmaceutico
US5232923A (en) 1988-03-18 1993-08-03 Mitsui Toatsu Chemicals, Incorporated Catechol derivatives and pharmaceutical preparations containing same
US5166317A (en) 1988-10-31 1992-11-24 Houston Biotechnology Incorporated Neurotrophic factor
US5215969A (en) 1989-08-11 1993-06-01 Hahnemann University Dopaminergic neurotrophic factor for treatment of Parkinson's disease
US5620971A (en) 1991-05-09 1997-04-15 Vertex Pharmaceuticals Incorporated Biologically active acylated amino acid derivatives
US5744485A (en) 1994-03-25 1998-04-28 Vertex Pharmaceuticals Incorporated Carbamates and ureas as modifiers of multi-drug resistance
IL115685A (en) * 1994-11-16 2000-08-31 Vertex Pharma Amino acid derivatives pharmaceutical compositions containing the same and processes for the preparation thereof
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5717092A (en) 1996-03-29 1998-02-10 Vertex Pharmaceuticals Inc. Compounds with improved multi-drug resistance activity
US5811434A (en) 1996-11-13 1998-09-22 Vertex Pharmacueticals Incorporated Methods and compositions for stimulating neurite growth
US5840736A (en) 1996-11-13 1998-11-24 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
US5780484A (en) 1996-11-13 1998-07-14 Vertex Pharmaceuticals Incorporated Methods for stimulating neurite growth with piperidine compounds
US5935989A (en) * 1996-12-31 1999-08-10 Gpi Nil Holdings Inc. N-linked ureas and carbamates of heterocyclic thioesters
ZA98825B (en) * 1997-02-27 1998-10-19 Guilford Pharm Inc Method of using neurotrophic carbamates and ureas

Also Published As

Publication number Publication date
EP1107757A2 (en) 2001-06-20
HUP0103166A3 (en) 2002-10-28
NO20010946D0 (no) 2001-02-23
EA200100271A1 (ru) 2001-10-22
CZ2001274A3 (cs) 2001-09-12
JP2002523367A (ja) 2002-07-30
IL140958A0 (en) 2002-02-10
MXPA01001937A (es) 2002-04-24
AU5687999A (en) 2000-03-14
SK2562001A3 (en) 2001-09-11
PL346759A1 (en) 2002-02-25
WO2000010553A2 (en) 2000-03-02
NO20010946L (no) 2001-02-23
US6242468B1 (en) 2001-06-05
CN1313767A (zh) 2001-09-19
BG105340A (en) 2001-12-29
HUP0103166A2 (hu) 2002-05-29
CA2341530A1 (en) 2000-03-02
KR20010072992A (ko) 2001-07-31
WO2000010553A3 (en) 2000-05-18

Similar Documents

Publication Publication Date Title
BR0110079A (pt) Combinação de compostos orgânicos
BR9912988A (pt) Composição farmacêutica e método de desenvolvimento de atividade neuronial em animal
IL142824A (en) Lipoic acid derivatives and their use as anti metabolic agents
BR0113136A (pt) sistema computadorizado e método para projetar, planejar, modificar ou manter uma ou mais redes de comunicação
BR9714739A (pt) Composição farmacêutica para reduzir a depressão respiratória e os efeitos colaterais inerentes de compostos opióides mu
BR0210568A (pt) Conjugado, uso de um conjugado, composição farmacêutica, e, método para tratar câncer em um mamìfero
BR0110521A (pt) Carbamatos azabicìclicos e seu uso como agonistas de receptores de alfa-7 acetilcolina nicotìnico
BR0207775A (pt) Lipossomos anfotéricos métodos para carregamento dos mesmos com ingredientes ativos e sua utilização
NO981944L (no) Lipopolyaminer som transfeksjonsmidler samt farmas÷ytisk anvendelse derav
BR9712834A (pt) Esteres e amidas heterocìclicos
BRPI0515012A (pt) substáncia quìmica, composição e formulação farmacêutica, método de tratamento, método de inibição de pelo menos uma enzima que utiliza atp e uso
TR200102029T2 (tr) 1-Heterosiklil ikameli diarilaminler.
ATE305468T1 (de) Chinuclidincarbamat derivate und deren verwendung als m3 antagonisten
NO20042964L (no) Spiroazasykliske forbindelser som monoaminreseptormodulatorer
YU83600A (sh) Adenozin a3 receptorski modulatori
BR0112631A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, composição farmacêutica, pacote, métodos de reduzir a condutáncia de cálcio de um receptor de capsaicina e de tratar um mamìfero e uso de um composto
DE60231868D1 (de) Folat-mimetika und deren folatrezeptorbindende konjugate
BR9909077A (pt) Uso de um antagonista para a osm ou um receptor de osm, composição farmacêutica, e, ensaio para a identificação de um antagonista da osm
PT1042301E (pt) Novos derivados de acilguanidina como inibidores da absorcao ossea e como antagonistas do receptor da vitronectina
BR9814040A (pt) Agudo no pulmão com fibrose com antagonistas de avb6
BR0316305A (pt) Composto ou um sal farmaceuticamente aceitável do mesmo, métodos para tratar a dor em um animal, para estimular a função do receptor opióide em uma célula, para preparar uma composição, e para tratar diarréia em um animal, composição, e kit
ATE231872T1 (de) Thiazolopyrimidinderivate
BR9713338A (pt) Benzonaftiridinas como terapêuticos brÈnquicos.
BRPI0518580A2 (pt) mÉtodo para melhorar a depuraÇço hepÁtica de substÂncias xenobiàticas em um animal, kit adequado para alimentar Ácido lipàico a um animal, meio para comunicar informaÇço, composiÇço, e, uso da composiÇço que compreende Ácido lipàico
BR0317229A (pt) Composição e uso de agonista completo de alfa7nachr

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 4O, 5O, 6O, 7O E 8O ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 1913 DE 04/09/2007.